List view / Grid view
The acquisition, which has a value of approximately $3.2 billion,…
The acquisition, which has a value of approximately $3.2 billion, is set to support development of small molecule oral integrin therapies for conditions such as ulcerative colitis.
Eli Lilly and Company’s $610 million acquisition of Akouos will…
Eli Lilly and Company’s $610 million acquisition of Akouos will fast-track gene therapies that restore, improve and preserve hearing for patients worldwide.
In a high-risk patient cohort, treatment with the combination of…
In a high-risk patient cohort, treatment with the combination of bamlanivimab and etesevimab reduces COVID-19 related hospitalisation and death by 87 percent.
Data from a Phase III trial shows high-risk patients treated…
Data from a Phase III trial shows high-risk patients treated with bamlanivimab and etesevimab were 70 percent less likely to be hospitalised due to COVID-19.
The neutralising antibody therapy bamlanivimab (LY-CoV555) is authorised for emergency…
The neutralising antibody therapy bamlanivimab (LY-CoV555) is authorised for emergency use in recently diagnosed patients who are at risk of developing severe COVID-19.
Eli Lilly has given an update on its neutralising antibody…
Eli Lilly has given an update on its neutralising antibody programmes, including its combination therapy in patients with COVID-19.
The first patient has been dosed in the Chinese Phase…
The first patient has been dosed in the Chinese Phase I trial of JS016 in healthy people who do not have a COVID-19 diagnosis.
The enterprise announced the initiation of the LY-CoV555 COVID-19 antibody…
The enterprise announced the initiation of the LY-CoV555 COVID-19 antibody treatment trial at medical centres across the US.
The enterprise announced its drug OLUMIANT® (baricitinib) and an investigational…
The enterprise announced its drug OLUMIANT® (baricitinib) and an investigational antibody will enter clinical trials in US COVID-19 patients later this month.
The developers have announced solanezumab failed to show disease-modifying properties…
The developers have announced solanezumab failed to show disease-modifying properties against dominantly inherited Alzheimer's disease (DIAD).
The pharmaceutical industry saw some notable mergers and acquisitions in…
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
